In this study we examined the effects of long-term treatment of 19 pat
ients with primary hypertension with the beta(1)-adrenoceptor antagoni
st atenolol on norepinephrine and epinephrine kinetics, at rest and du
ring sympathoadrenal stimulation by lower body negative pressure. Nore
pinephrine and epinephrine kinetics were measured by using the radiois
otope-dilution technique by steady-state infusion of tritiated norepin
ephrine and epinephrine. The patients were studied before and at the e
nd of 3 months of treatment with atenolol (50 or 100 mg daily). A cont
rol group of four normotensive subjects was studied before and after 3
months without any drug treatment. In this group, only arterial blood
samples were collected without infusion of the tritiated catecholamin
es. Atenolol decreased blood pressure and heart rate, but forearm vasc
ular resistance was not affected by atenolol. During atenolol, baselin
e arterial plasma epinephrine decreased from 0.23 +/- 0.02 to 0.17 +/-
0.01 nM (p < 0.05), and this was accompanied by a decrease in total b
ody epinephrine spillover from 0.50 +/- 0.05 to 0.35 +/- 0.04 nmol/min
(p < 0.05). In the control group, arterial plasma epinephrine had not
decreased after 3 months. In addition, the increment of arterial plas
ma epinephrine during lower body negative pressure at -40 mm Hg was at
tenuated during atenolol. Atenolol had no effect on total body and for
earm norepinephrine spillover rates, either at rest or during lower bo
dy negative pressure. Clearance rates of epinephrine and norepinephrin
e were not significantly affected by atenolol. These results suggest t
hat treatment of patients with primary hypertension with the beta(1)-a
drenoceptor blocker atenolol inhibits the adrenomedullary secretion of
epinephrine, but it does not affect the biochemical indices of sympat
honeural activity. It remains speculative whether this selective effec
t of atenolol on epinephrine secretion contributes to its hypotensive
action and to its cardioprotective effects in the long term.